Clinical Trial Update: Chemoradiation Plus Weekly c225 Against Locoregionally Advanced Nasopharyngeal Carcinoma (NPC) [Phase 1, Phase 2]

View source ↗

Summary

This completed Phase 1/2 trial from Jiangsu Cancer Institute & Hospital evaluated chemoradiation with weekly cetuximab (c225) in patients with locoregionally ad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nasopharyngeal Carcinoma

Drugs mentioned

• ERBITUX (cetuximab)

Snippet

Sponsor: Jiangsu Cancer Institute & Hospital | Conditions: Nasopharyngeal Carcinoma | Phase 1, Phase 2 | Status: COMPLETED